When the Trump administration dropped the drug rebate rule it introduced back in January – a rule that intended to prohibit pharmacy benefit managers (PBMs) from pocketing some of the rebates they should be passing along to patients – the decision sent shockwaves through the healthcare industry, particularly the pharma sector.

PBMs were obviously pleased, and many healthcare and consumer advocates outraged. Understandably so, given how expensive some drugs are and how impossible it is for some people to purchase the life-saving medications they need – insulin especially.

However, almost everyone engaging in this debate is failing to see one very important thing: More legislation isn’t the answer.

Read More

Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.

Privacy is important. We do not share registrant information with anyone outside of Numerof & Associates. For details, please see our Privacy Policy. Subscribers to our mailings can unsubscribe instantly at any time.